Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CAR T-cell therapy for pancreatic cancer.

Literature DB >> 28346697

CAR T-cell therapy for pancreatic cancer.

Carl J DeSelm¹, Zachary E Tano², Anna M Varghese³, Prasad S Adusumilli^1,2.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: CAR T cells; adoptive cell therapy; checkpoint blockade; chimeric antigen receptor; immunotherapy

Mesh：

Substances：

Year: 2017 PMID： 28346697 PMCID： PMC5491361 DOI： 10.1002/jso.24627

Source DB: PubMed Journal: J Surg Oncol ISSN： 0022-4790 Impact factor: 3.454

143 in total

1. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors: Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal: Cancer Immunol Res Date: 2013-07 Impact factor: 11.151

2. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Authors: Cor H J Lamers; Ralph Willemsen; Pascal van Elzakker; Sabine van Steenbergen-Langeveld; Marieke Broertjes; Jeannette Oosterwijk-Wakka; Egbert Oosterwijk; Stefan Sleijfer; Reno Debets; Jan W Gratama
Journal: Blood Date: 2010-10-01 Impact factor: 22.113

3. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

Authors: H Safran; M Steinhoff; S Mangray; R Rathore; T C King; L Chai; K Berzein; T Moore; D Iannitti; P Reiss; T Pasquariello; P Akerman; D Quirk; R Mass; L Goldstein; U Tantravahi
Journal: Am J Clin Oncol Date: 2001-10 Impact factor: 2.339

Review 4. CAR therapy: the CD19 paradigm.

Authors: Michel Sadelain
Journal: J Clin Invest Date: 2015-09-01 Impact factor: 14.808

5. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors: Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal: J Immunother Date: 2013-02 Impact factor: 4.456

6. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors: C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal: Cancer Immunol Immunother Date: 2008-04-30 Impact factor: 6.968

7. Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma.

Authors: J Emmrich; I Weber; M Nausch; G Sparmann; K Koch; M Seyfarth; M Löhr; S Liebe
Journal: Digestion Date: 1998 Impact factor: 3.216

8. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3.

Authors: Uddalak Bharadwaj; Min Li; Changyi Chen; Qizhi Yao
Journal: Mol Cancer Res Date: 2008-11 Impact factor: 5.852

9. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.

Authors: Gary Tozbikian; Edi Brogi; Kyuichi Kadota; Jeffrey Catalano; Muzaffar Akram; Sujata Patil; Alice Y Ho; Jorge S Reis-Filho; Britta Weigelt; Larry Norton; Prasad S Adusumilli; Hannah Yong Wen
Journal: PLoS One Date: 2014-12-15 Impact factor: 3.240

10. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.

Authors: Sofia R Gameiro; Jack P Higgins; Matthew R Dreher; David L Woods; Goutham Reddy; Bradford J Wood; Chandan Guha; James W Hodge
Journal: PLoS One Date: 2013-07-24 Impact factor: 3.240

24 in total

Review 1. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.

Authors: Andres Garcia-Sampedro; Gabriella Gaggia; Alexander Ney; Ismahan Mahamed; Pilar Acedo
Journal: J Clin Med Date: 2021-02-03 Impact factor: 4.241

Review 2. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors: Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal: Target Oncol Date: 2018-06 Impact factor: 4.493

CAR T-cell therapy for pancreatic cancer.

1. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

2. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

3. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

Review 4. CAR therapy: the CD19 paradigm.

5. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

6. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

7. Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma.

8. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3.

9. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.

10. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.

Review 1. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.

Review 2. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

3. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Review 4. CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.

Review 5. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

6. EUS-guided cell transplantation: Planting seeds of hope.

Review 7. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Review 8. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.

Review 9. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.

Review 10. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy.